Dr. Lujing Wang has extensive experience in the areas of health economics, pricing, and market access.  He has assisted many leading pharmaceutical and biotech companies in developing pricing, reimbursement, market access, and evidence generation strategies in the US, the EU, and key emerging markets.  He is also a thought leader in assessing future market access landscape, defining requirements for the market access function, and designing state-of-art infrastructures and processes to help clients face tomorrow’s market access challenges.

Prior to joining Campbell Alliance, Dr. Wang led client engagements with Analytica International, a global outcomes research organization.  Dr. Wang has also held positions at the Massachusetts Division of Health Care Finance and Policy, the National Lab of Medical Molecular Biology in Beijing, China, and the University of California, San Francisco.

Dr. Wang earned his Master of Public Health from Harvard University.  He also earned a Doctor of Medicine degree from Peking Union Medical College and his undergraduate degree from Peking University.